Onkologie. 2014:8(5):212-218 [Urol. praxi, 2014; 15(2): 55-60]

The importance of cooperation between urologist and oncologist in the treatment of castration-resistant

Otakar Čapoun

Urologická klinika VFN a 1. LF UK v Praze

prostate cancer

Treatment of prostate cancer has become more complex in recent years, mainly due to the onset of new cytotoxic agents, antiandrogens

and radiopharmaceuticals. The problem of sequential therapy will probably never be resolved, because there will always be new drugs

involved in the therapeutic algorithms. It is always necessary to take into account the patient’s preferences, his performance status and

comorbidities, and unfortunately also the possibilities of different departments. Groups of patients entering clinical trials are highly

selected and do not reflect the reality of daily practice. Multidisciplinary teams with participation of urologist, clinical and radiation

oncologists and other specialities are thus of great importance. The consultation can select an appropriate treatment strategy for each

patient individually, including the possibility to participate in clinical trials at the respective departments. Abiraterone and enzalutamide

will soon be approved for use in metastatic carcinoma before chemotherapy with indisputable advantage of a favourable side effects

profile. Effective cytotoxic therapy will always be available in case of failure of these antiandrogens.

Keywords: castration-resistant prostate cancer, abiraterone, enzalutamide, multidisciplinary team

Published: October 16, 2014  Show citation